Texas

At a recent Demy-Colton Virtual Salon, Michael Gaito, head of healthcare investment banking at J.P. Morgan, discussed the strength of capital raises despite COVID-19 and the resilient state of the biotech sector in the run-up to the Presidential election in November and the virtual J.P. Morgan Healthcare Conference (and the virtual Biotech Showcase) in January, with Dennis Purcell, founder of Aisling Capital LLC.

Starting with $30 million in seed financing in April, Taysha sprinted through a $95 million Series B in August and rounded the corner this Thursday to bring in $157 million for its IPO.

The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The acquisition is expected to bolster ACADIA’s clinical pipeline to include non-opioid pain therapies that have potential non-addictive properties and reduced side effects typically seen with current opioid treatments.

A study published in Nature last week explains why certain kinds of cancer cells often spread to the lymph nodes before various organs within the body.

Niclosamide is an oral anthelminthic drug. It was first approved by the U.S. Food and Drug Administration (FDA) in 1982 and is included in the World Health Organization (WHO)’s list of essential medicines.

Texas-based Taysha Gene Therapies announced last week that it had concluded a Series B round of financing worth $95 million.

Texas-based Reata Pharmaceuticals announced the potential delay Monday when it released its 2nd quarter financial report.

As the world continues to navigate through the coronavirus pandemic, many biopharma companies are surging ahead with job creations. Check out these companies that have made recent job expansion announcements.